Patrys Limited · ASX:PAB

Patrys — Investor Presentation (May 2021)

25 slides from Patrys's investor presentation, May 2021

  1. Slide 1: Investor Presentation May 2021

    INVESTOR PRESENTATION May 2021

  2. Slide 2: Safe harbour statement

    Safe harbour statement The following material is for general information purposes only and is not to be relied upon for the making of an investment decision. Any investment in Patrys Limited ACN 123 055 363 (Patrys) is subject to investment risk including the possibility of loss of capital invested

  3. Slide 3: Investment summary

    Investment summary • Deoxymabs are the first antibody platform able to naturally enter cells and target DNA damage repair (DDR) • Recent transactions in cancer drugs targeting DDR, and sales of PARP inhibitors (2019/20 sales >US$1.5 bn) highlight the commercial attractiveness of this space • Patrys

  4. Slide 4: Company snapshot

    Company snapshot Shares 1.81B Patrys (ASX: PAB) – 12-month price and volume Market cap A$47.2M Cash 1 A$12.0M Last qtr burn 1 (A$1.20M) Headquarters Melbourne Board John Read(Chair) James Campbell (CEO & MD) Pamela Klein (NED) Suzy Jones (NED) Michael Stork (NED) Substantial Dr Dax Marcus Calder – 1

  5. Slide 5: Board of Directors

    Board of Directors John Read Chairman Dr Pamela M. Klein • Experienced Chairman and Director in public, • Former VP, Development at Genentech, led development private and government organisations of a large portfolio of drugs • Chief Medical Officer of Intellikine (acquired by • Extensive career in

  6. Slide 6: Technology Overview

    | > oben Technology Overview ie —_ « “

  7. Slide 7: First anticancer antibody therapeutic targeting DDR

    First anticancer antibody therapeutic targeting DDR • Patients with systemic lupus erythematosis (SLE) generate antibodies against antigens from their own tissues and cells • An antibody which binds to DNA, 3E10, was isolated from a mouse model of SLE • 3E10 has a unique combination of properties th

  8. Slide 8: Patrys' deoxymab platform

    Patrys’ deoxymab platform • Patrys’ deoxymab platform is based on humanised versions of the mouse Mouse Humanised 3E10 antibodies • Global rights to 3E10 antibodies for the treatment of cancer were acquired in 2016 • Patrys has created humanised versions of the 3E10 antibodies for 3E10 - IgG PAT-DX3

  9. Slide 9: Targeting DNA damage is effective for treating cancer

    Targeting DNA damage is effective for treating cancer • Low-level damage occurs to DNA normally, but is usually fixed by DNA Normal tissues damage repair (DDR) systems DNA damage DNA damage repair (DDR) • Many current cancer treatments exploit the vulnerability cancer cells have from damage to their

  10. Slide 10: Deoxymab platform offers multiple therapeutic approaches

    Deoxymab platform offers multiple therapeutic approaches Single Agent Combination Therapies Targeted Therapies + • Many cancers have pre-existing defects • DNA damage can be increased by • Deoxymabs can direct delivery of toxic in their DNA damage repair (DDR) combining deoxymabs with existing DNA-

  11. Slide 11: Deoxymab programs

    Deoxymab programs - 11 -

  12. Slide 12: Single agent – synthetic lethality is a proven approach

    Single agent – synthetic lethality is a proven approach • Many cancer cells have defects in their DNA damage repair (DDR) systems • Redundancy means that these cancer cells usually can divide and survive, despite these defects • Further blocking the DDR systems with drugs can result in a build-up of

  13. Slide 13: Single agent – deoxymabs offer new options

    Single agent – deoxymabs offer new options • Patrys’ deoxymab platform provides an antibody option for generating Synthetic Lethality With Deoxymabs synthetic lethality to treat cancer • The potential benefits of using deoxymab antibodies for synthetic lethality include: • Cancer targeting: attracte

  14. Slide 14: Single agent – deoxymabs for treatment of glioblastoma

    Single agent – deoxymabs for treatment of glioblastoma • Glioblastoma (GBM) is the most common form of primary brain cancer, Glioblastoma cells with approximately 23,000 new cases diagnosed in the US each year control • GBM is highly aggressive with few effective treatment options (5-year Deoxymab s

  15. Slide 15: Single agent – deoxymabs for breast cancer metastases

    Single agent – deoxymabs for breast cancer metastases • Approximately 230,000 women are diagnosed with breast cancer in the US each year TNBC 1 Brain Metastases Model 100 • 10%-15% have Triple Negative Breast Cancer (TNBC), an aggressive form with deficiencies in the BRCA1 gene (DNA damage repair) 8

  16. Slide 16: Single agent – many solid tumors have DDR mutations

    Single agent – many solid tumors have DDR mutations Cancer incidence rates DDR mutation Opportunity (US cases p.a.)1 rates2 size Breast 271k 16% 43k Pancreatic 57k 15% 9k Ovarian 23k 20% 5k Endometerial 62k 34% 21k Colon 101k 15% 15k American Cancer Society - Cancer Facts & Figures 2019 Heeke et al.

  17. Slide 17: Combination therapies – doubling down on DNA damage

    Combination therapies – doubling down on DNA damage • Deoxymabs can be combined with radiation or chemotherapy drugs to increase the levels of DNA damage: Combination therapies • Radiation/chemo: damage DNA in cancer cells • Deoxymabs: reduce ability of cancer cells to repair DNA damage Chemo & PARP

  18. Slide 18: Combination therapies – improving glioblastoma treatments

    Combination therapies – improving glioblastoma treatments • Radiation is a mainstay treatment for glioblastoma (GBM) patients Radiation + Deoxymabs improve survival and is used: • as a monotherapy (less frequently) • post-surgical removal of tumour tissue 71% • in combination with the drug temozolom

  19. Slide 19: Targeted therapies – Deoxymabs provide new opportunities

    Targeted therapies – Deoxymabs provide new opportunities Cancer Targeting Nucleus Targeting x800 payload deoxymab alone + payload • Deoxymabs are attracted to the DNA released from tumors • Deoxymabs are able to enter the cell and penetrate into the nucleus • This “cancer seeking” activity can be us

  20. Slide 20: Commercial landscape

    Commercial landscape - 20 -

  21. Slide 21: Recent deals for antibody and synthetic lethality assets

    Recent deals for antibody and synthetic lethality assets Recent pre-clinical transactions (licensing, asset and corporate)1 US$6b US$4,000m US$4,000m US$3,065m US$2,070m US$1,3000m US$1,076m US$1,200m US$865m US$600m Deal date 1Q19 1Q19 3Q19 1Q20 2Q20 2Q20 2Q20 3Q20 1Q210 2Q210 Co- Strategic Strateg

  22. Slide 22: DDR assets attracting commercial interest

    DDR assets attracting commercial interest - 22 -

  23. Slide 23: Timeline

    Timeline CY21 CY22 1Q 2Q 3Q 4Q 1Q 2Q Additional animal models PK and non - GLP Tox IND-enabling File activities for MCB , USD and DSD and scale-up run GMP production and formulation Aust-HREA (IND) PAT-DX1 Complete GLP toxicology cell line develop- ment Phase 1 Additional animal models (grants and d

  24. Slide 24: Anticipated newsflow / Milestones

    Anticipated newsflow / Milestones PAT-DX1 stable cell line development completed Q4 2020 ✓ PAT-DX1 & PAT-DX3 comparative animal studies initiated Q4 2020 ✓ PAT-DX1 non-GLP toxicology and pharmacokinetic studies completed Q1 2021 ✓ PAT-DX1 master cell bank completed Q2 2021 PAT-DX3 pre-clinical studi

  25. Slide 25: Contact

    CONTACT CONTACT Dr. James Campbell CEO and Managing Director +61 3 9670 3273 info@patrys.com www.patrys.com Patrys Limited (ASX:PAB)

Patrys — Investor Presentation (May 2021) on 6ix